MBX Biosciences reports Q1 EPS (51c), consensus (58c)

“We continue to make excellent progress across our pipeline in 2026, including advancement toward initiation of our Phase 3 trial of once-weekly canvuparatide following a successful End-of-Phase 2 meeting with the FDA,” said Kent Hawryluk, President and Chief Executive Officer of MBX Biosciences (MBX). “Now we look forward to presenting our full Phase 2 Avail(TM) results, including one-year open-label extension data for canvuparatide, while continuing to advance a growing obesity pipeline enabled by our Precision Endocrine Peptide platform. With a world-class leadership team and a strong balance sheet, we are well positioned to execute on our goal of delivering improved, long-acting and well-tolerated peptide therapies for patients.”